NJ.com -- When Francois Nader arrived at NPS Pharmaceuticals in 2006, the company was reeling from a major drug development setback, a shortage of money and serious questions about its future.
NJ.com -- When Francois Nader arrived at NPS Pharmaceuticals in 2006, the company was reeling from a major drug development setback, a shortage of money and serious questions about its future.
